April 01, 2026 02:32 am (IST)
Follow us:
Strides Arcolab signs agreement with Gilead Sciences
Bangalore/Kolkata, Jan 20 (IBNS): Strides Arcolab Limited (Strides) on Tuesday announced that it has entered into a licensing agreement with Gilead Sciences, Inc. under which Gilead has extended non-exclusive rights to Strides to manufacture and distribute Tenofovir Alafenamide (TAF), both as a single agent product and in combination with other drugs.
The license being granted to Strides extends to 112 countries, which together account for more than 30 million people living with HIV.
As part of the licensing agreement, pending U.S. Food and Drug Administration (US FDA) approval of the Gilead product, Strides will receive a technology transfer from Gilead, enabling Strides to manufacture low-cost versions of TAF for developing countries.
TAF is a novel nucleotide reverse transcriptase inhibitor that has demonstrated high antiviral efficacy at a dose 10 times lower than Gilead’s Viread (tenofovir disoproxil fumarate), as well as an improved renal and bone safety profile.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
Latest Headlines
PwC India announces leadership transition in Deals Business
Tue, Mar 31 2026
DBS Bank India launches relationship-led banking for 'India’s globally mobile, emerging affluent'
Tue, Mar 31 2026
Major expansion ahead: Govt clears 29 proposals under ECMS
Tue, Mar 31 2026
Over 7.83 crore enterprises registered on Udyam Registration Portal (URP), says Minister
Mon, Mar 30 2026
2026 economic crisis ahead? Robert Kiyosaki shares investment plan
Sat, Mar 28 2026
Larsen & Toubro drops 3% despite securing ₹2,500 crore orders
Fri, Mar 27 2026